## Core Concept
Arsenic, in the form of arsenic trioxide, has a specific role in the treatment of certain hematological malignancies. It exerts its effect through various mechanisms, including induction of apoptosis and promotion of differentiation in cancer cells. The therapeutic use of arsenic is particularly noted in the management of acute promyelocytic leukemia (APL).

## Why the Correct Answer is Right
The correct answer, **C. Acute Promyelocytic Leukemia (APL)**, is the condition for which arsenic trioxide is specifically used. APL is a subtype of acute myeloid leukemia (AML) characterized by the abnormal accumulation of immature granulocytes (promyelocytes). Arsenic trioxide works by targeting the PML-RARA fusion protein, which is a result of the t(15;17) chromosomal translocation typical of APL. This action leads to the degradation of the fusion protein, thereby inducing apoptosis in APL cells and promoting the differentiation of the leukemic promyelocytes into mature cells.

## Why Each Wrong Option is Incorrect
- **Option A:** While certain types of cancer may be treated with a variety of chemotherapeutic agents, arsenic is not commonly used for the treatment of solid tumors like breast cancer.
- **Option B:** Arsenic is not typically used in the management of chronic myeloid leukemia (CML). CML is usually treated with tyrosine kinase inhibitors (TKIs) that target the BCR-ABL fusion protein resulting from the Philadelphia chromosome abnormality.
- **Option D:** Arsenic is not used in the treatment of non-Hodgkin lymphoma. The management of non-Hodgkin lymphoma often involves chemotherapy, radiation therapy, immunotherapy, or a combination of these, depending on the specific type and stage of the disease.

## Clinical Pearl / High-Yield Fact
A key point to remember is that arsenic trioxide is specifically used in the treatment of **Acute Promyelocytic Leukemia (APL)**, particularly in cases that are resistant to or have relapsed from all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy. The use of arsenic trioxide has significantly improved the outcomes in APL.

## Correct Answer: C. Acute Promyelocytic Leukemia.